MODULATING THE IMMUNE RESPONSE USING ANTIBODY-DRUG CONJUGATES
The invention provides methods and compositions for modulating the immune response in a subject, such as decreasing the activity of CD30 + T regulatory cells and increasing the ratio of CD8 + T cells to CD30 + T regulatory cells, through administration of antibody drug-conjugates that bind to CD30. The invention also provides articles of manufacture or kits comprising said antibody drug-conjugates that bind to CD30 for modulating the immune response.
1 . A method of decreasing the activity of CD30 + T regulatory (Treg) cells in a subject having cancer comprising administering to the subject an antibody-drug conjugate, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding portion thereof conjugated to a monomethyl auristatin.
2 . The method of claim 1 , wherein decreasing the activity of CD30 + Treg cells comprises a decrease in the number of CD30 + Treg cells.
3 . The method of claim 2 , wherein the number of CD30 + Treg cells is decreased relative to the number of one or more other types of CD4 + T cells.
4 . The method of claim 3 , wherein the one or more other types of CD4 + T cells comprise Th1 cells, Th2 cells or Th17 cells.
5 . The method of claim 4 , wherein the one or more other types of CD4 + T cells comprise Th1 CD30 + cells, Th2 CD30 + cells or Th17 CD30 + cells.
6 . The method of any one of claims 2 - 5 , wherein the number of CD30 + Treg cells is decreased relative to the number of CD30 + Treg cells in the subject prior to administration of the antibody-drug conjugate.
7 . The method of claim 1 , wherein decreasing the activity of CD30 + Treg cells comprises a decrease in the function of CD30 + Treg cells.
8 . The method of claim 7 , wherein the decrease in the function of CD30 + Treg cells is relative to the function of CD30 + Treg cells in a subject prior to administration of the antibody-drug conjugate.
9 . A method of increasing the ratio of CD8 + T cells to CD30 + T regulatory (Treg) cells in a subject having cancer comprising administering to the subject an antibody-drug conjugate, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding portion thereof conjugated to a monomethyl auristatin.
10 . A method of modulating the immune response in a subject having cancer comprising administering to the subject an antibody-drug conjugate, wherein the antibody-drug conjugate comprises an anti-CD30 antibody or an antigen-binding portion thereof conjugated to a monomethyl auristatin, wherein the modulation comprises increasing the ratio of CD8 + T cells to CD30 + T regulatory (Treg) cells in the subject.
11 . The method of claim 9 or 10 , wherein the ratio of CD8 + T cells to CD30 + Treg cells is increased relative to the ratio of CD8 + T cells to CD30 + Treg cells in the subject prior to the administration of the antibody-drug conjugate.
12 . The method of any one of claims 1 - 11 , wherein the CD30 + Treg cells are CD30 + inducible T regulatory (iTreg) cells or CD30 + peripheral T regulatory (pTreg) cells.
13 . The method of any one of claims 1 - 12 , wherein the monomethyl auristatin is monomethyl auristatin E (MMAE).
14 . The method of any one of claims 1 - 12 , wherein the monomethyl auristatin is monomethyl auristatin F (MMAF).
15 . The method of any one of claims 1 - 14 , wherein the anti-CD30 antibody is anti-CD30 antibody AC10.
16 . The method of claim 15 , wherein the anti-CD30 antibody is cAC10.
17 . The method of any one of claims 1 - 16 , wherein the anti-CD30 antibody of the antibody-drug conjugate comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises:
(i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
(ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and
(iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and
wherein the light chain variable region comprises:
(i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;
(ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and
(iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
18 . The method of any one of claims 1 - 17 , wherein the anti-CD30 antibody of the antibody-drug conjugate comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8.
19 . The method of any one of claims 1 - 17 , wherein the anti-CD30 antibody of the antibody-drug conjugate comprises a heavy chain variable region comprising an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO: 8.
20 . The method of any one of claims 1 - 19 , wherein the antibody-drug conjugate further comprises a linker between the anti-CD30 antibody or antigen-binding portion thereof and the monomethyl auristatin.
21 . The method of claim 20 , wherein the linker is a cleavable peptide linker.
22 . The method of claim 21 , wherein the cleavable peptide linker has a formula: -MC-vc-PAB-.
23 . The method of any one of claims 1 - 22 , wherein the antibody-drug conjugate is brentuximab vedotin.
24 . The method of any one of claims 1 - 23 , wherein the subject has been previously treated for the cancer.
25 . The method of claim 24 , wherein the subject did not respond to treatment or relapsed after first-line treatment.
26 . The method of any one of claims 1 - 23 , wherein the subject has not previously been treated for the cancer.
27 . The method of any one of claims 1 - 26 , wherein the cancer is a lymphoma.
28 . The method of claim 27 , wherein the lymphoma is a T-cell lymphoma.
29 . The method of claim 27 , wherein the lymphoma is a B-cell lymphoma.
30 . The method of claim 27 , wherein the lymphoma is a non-Hodgkin lymphoma.
31 . The method of claim 30 , wherein the non-Hodgkin lymphoma is a mature T-cell lymphoma.
32 . The method of claim 30 , wherein the non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL), anaplastic large cell lymphoma (ALCL) or cutaneous T-cell lymphoma (CTCL).
33 . The method of claim 32 , wherein the non-Hodgkin lymphoma is cutaneous T-cell lymphoma (CTCL).
34 . The method of claim 32 , wherein the non-Hodgkin lymphoma is anaplastic large cell lymphoma (ALCL).
35 . The method of claim 27 , wherein the lymphoma is a Hodgkin lymphoma.
36 . The method of claim 35 , wherein the subject has been previously treated for the Hodgkin lymphoma and the subject did not respond to treatment or relapsed after first-line treatment.
37 . The method of claim 36 , wherein the subject relapsed after autologous stem cell transplant.
38 . The method of claim 36 , wherein the subject relapsed after first-line treatment and the subject is ineligible for autologous stem cell transplant.
39 . The method of claim 35 , wherein the subject has not been previously treated for the Hodgkin lymphoma.
40 . The method of claims 35 - 39 , wherein the Hodgkin lymphoma is classical Hodgkin lymphoma (cHL).
41 . The method of claim 40 , wherein the classical Hodgkin lymphoma (cHL) is advanced cHL.
42 . The method of claim 40 or 41 , wherein the subject has been previously treated for cHL.
43 . The method of claim 40 or 41 , wherein the subject has not been previously treated for cHL.
44 . The method of any one of claims 1 - 43 , wherein the method further comprises administering one or more additional therapeutic agents capable of modulating the immune response.
45 . The method of claim 44 , wherein the one or more additional therapeutic agents is not an antibody or antigen-binding fragment thereof.
46 . The method of claim 44 , wherein the one or more additional therapeutic agents is an antibody or antigen-binding fragment thereof.
47 . The method of any one of claims 1 - 43 , wherein the method further comprises administering one or more additional therapeutic agents.
48 . The method of claim 47 , wherein the one or more additional therapeutic agents is a chemotherapy regimen consisting essentially of doxorubicin, vinblastine, and dacarbazine (AVD).
49 . The method of claim 47 , wherein the one or more additional therapeutic agents is a chemotherapy regimen consisting essentially of Cyclophosphamide, Doxorubicin, and Prednisone (CHP).
50 . The method of claim 47 , wherein the one or more additional therapeutic agents is an alkylating agent, an anthracycline, an antibiotic, an antifolate, an antimetabolite, an antitubulin agent, an auristatin, a chemotherapy sensitizer, a DNA minor groove binder, a DNA replication inhibitor, a duocarmycin, an etoposide, a fluorinated pyrimidine, a lexitropsin, a nitrosourea, a platinol, a purine antimetabolite, a puromycin, a radiation sensitizer, a steroid, a taxane, a topoisomerase inhibitor, and/or a vinca alkaloid.
51 . The method of claim 47 , wherein the one or more additional therapeutic agents is selected from the group consisting of adriamycin, an androgen, anthramycin (AMC), asparaginase, 5-azacytidine, azathioprine, bleomycin, busulfan, buthionine sulfoximine, camptothecin, carboplatin, carmustine (BSNU), CC-1065, chlorambucil, cisplatin, colchicine, cyclophosphamide, cytarabine, cytidine arabinoside, cytochalasin B, dacarbazine, dactinomycin (formerly actinomycin), daunorubicin, decarbazine, docetaxel, doxorubicin, an estrogen, 5-fluordeoxyuridine, 5-fluorouracil, gramicidin D, hydroxydaunorubicin, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine (CCNU), mechlorethamine, melphalan, 6-mercaptopurine, methotrexate, mithramycin, mitomycin C, mitoxantrone, nitroimidazole, paclitaxel, plicamycin, prednisone, prednisolone, procarbizine, streptozotocin, tenoposide, 6-thioguanine, thioTEPA, topotecan, vinblastine, vincristine, vinorelbine, VP-16 and VM-26.
52 . The method of claim 47 , wherein the subject has cHL that has not been previously treated and wherein the one or more additional therapeutic agents are adriamycin, dacarabazine and vinblastine.
53 . The method of claim 52 , wherein the cHL is advanced cHL.
54 . The method of claim 47 , wherein the subject has a mature T-cell lymphoma that has not been previously treated and wherein the one or more additional therapeutic agents are cyclophosphamide, hydroxydaunorubicin and prednisone.
55 . The method of claim 47 , wherein the subject has a mature T-cell lymphoma that has not been previously treated and wherein the one or more additional therapeutic agents are cyclophosphamide, hydroxydaunorubicin and prednisolone.
56 . The method of claim 47 , wherein the one or more additional therapeutic agents is an antibody or antigen-binding fragment thereof.
57 . The method of any one of claims 1 - 56 , further comprising treating the subject with irradiation.
58 . The method of claim 34 , wherein the anaplastic large cell lymphoma (ALCL) is a systemic anaplastic large cell lymphoma (sALCL).
59 . The method of claim 33 , wherein the cutaneous T-cell lymphoma (CTCL) is a mycosis fungoides (MF).
60 . The method of claim 59 , wherein the mycosis fungoides (MF) is a CD30-positive mycosis fungoides (MF).
61 . The method of claim 33 , wherein the cutaneous T-cell lymphoma (CTCL) is a primary cutaneous anaplastic large cell lymphoma (pcALCL).
62 . The method of claim 61 , wherein the subject has received prior systemic therapy.